Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children
- 18 June 2021
- journal article
- research article
- Published by Springer Nature in Pediatric Drugs
- Vol. 23 (4) , 395-401
Abstract
Objectives This study aimed to assess the incidence of amikacin plasma peak concentration (Cmax) below 60 mg·L−1 in critically ill children receiving an amikacin dosing regimen of 30 mg kg−1·day−1. Secondary objectives were to identify factors associated with low Cmax and to assess the incidence of acute kidney injury (AKI). Methods A retrospective observational study was performed in two French pediatric intensive care units. All admitted children who received 30 mg·kg−1 amikacin and had a Cmax measurement were eligible. Clinical and biological data, amikacin dose, and concentrations were collected. Results In total, 30 patients were included, aged from 3 weeks to 7 years. They received a median amikacin dosage of 30 mg kg−1·day−1 (range 29–33) based on admission body weight (BW), corresponding to 27 mg kg−1·day−1 (range 24–30) based on actual BW. Cmax was < 60 mg·L−1 in 21 (70%) children and none had a Cmax ≥ 80 mg·L−1. Among the 15 patients with a measured minimum inhibitory concentration (MIC), 13 (87%) had a Cmax/MIC ratio > 8. Univariate analysis showed that factors associated with Cmax < 60 mg·L−1 were high estimated glomerular filtration rate (p = 0.015) and low blood urea concentration (p = 0.001). AKI progression or occurrence was observed after amikacin administration in two (7%) and six (21%) patients, respectively. Conclusions Despite the administration of the maximal recommended amikacin dose, Cmax was below the pharmacokinetic target in 70% of our pediatric population. Further studies are needed to develop a pharmacokinetic model in a population of critically ill children to optimize target attainment.Keywords
This publication has 28 references indexed in Scilit:
- PELOD-2Critical Care Medicine, 2013
- Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Critical Care, 2013
- Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoringMedecine Et Maladies Infectieuses, 2012
- Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicityInternational Journal of Antimicrobial Agents, 2011
- Actualités en antibiothérapie — Aminosides toujours et encore: bon usage et suivi thérapeutiqueRéanimation, 2010
- Extended-interval gentamicin: Population pharmacokinetics in pediatric critical illnessPediatric Critical Care Medicine, 2010
- Optimizing Use of Aminoglycosides in the Critically IllSeminars in Respiratory and Critical Care Medicine, 2007
- International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*Pediatric Critical Care Medicine, 2005
- Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patientIntensive Care Medicine, 1996
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987